Online Exclusives

Online Exclusives

U.S. Hospitals Warn About Looming Chemotherapy Shortages

Several U.S. hospitals have reported short supplies of two chemotherapy drugs, vincristine and etoposide. The former is used to treat leukemia and the latter...

Trump Administration Reveals Plans to Lower Drug Prices

In a recent speech at the White House, President Donald Trump unveiled new initiatives to curb high drug prices, including removing barriers to generic-drug...

FDA Cracks Down on Unapproved Stem Cell Clinics

The U.S. Food and Drug Administration (FDA) filed two complaints earlier this month seeking permanent injunctions against two stem cell clinics, U.S. Stem Cell...

Cancer Doctors Are Still Hazy on Medical Marijuana

According to a survey conducted by researchers at Dana-Farber Cancer Institute, many U.S. cancer doctors have recommended medical marijuana to their patients to manage...

FDA Approves First Biosimilar for Anemia Treatment

The U.S. Food and Drug Administration (FDA) approved epoetin alfa-epbx as a biosimilar to epoetin alfa for the treatment of anemia caused by chronic...

NIH Sued Over Plans to Grant Exclusive License to Gilead’s CAR T-Cell Technology

Consumer advocacy group Knowledge Ecology International is suing to prevent the National Institutes of Health (NIH) from awarding a worldwide exclusive license to Gilead Sciences for...

FDA Rejects Rituximab Biosimilar’s Application

The U.S. Food and Drug Administration (FDA) has decided against approving the biologics license application (BLA) for GP2013, a proposed rituximab biosimilar. Sandoz, the biosimilar’s...

FDA Approves First and Only Antidote for Factor Xa Inhibitors Reversal

The U.S. Food and Drug Administration (FDA) granted approval to andexanet alfa, also known as coagulation factor Xa (recombinant), inactivated-zhzo, for the reversal of...

FDA Chief Questions Protections on Drug Rebates

A federal law that protects drug rebates between pharmacy benefit managers, drug manufacturers, and insurers could be reinterpreted to prevent these types of “kickbacks,”...

Emicizumab-kxwh Granted Breakthrough Therapy Designation for Hemophilia Without Inhibitors

The U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation to emicizumab-kxwh for the treatment of patients with hemophilia A without factor VIII...
Advertisement

Current Issue

May 2018, Volume 4, Issue 6

This issue features a look at the hidden costs of importing lower-cost drugs, the optimal hemophilia treatment, the limits of genetic testing, and more.